'Combination Product Agreement Meetings' Coming Soon From US FDA
Executive Summary
The meetings are tied to requirements from the 2016 21st Century Cures legislation. They could offer more development certainty for sponsors by allowing informal agreements with the agency on pre- and post-market issues.
You may also be interested in...
More Talk, Less Work: US FDA Outlines Expectations For Combo Products Discussions
New FDA draft guidance says manufacturers of combination products should first review existing combination product guidances and submit questions before asking for a combination product agreement meeting with regulators to get clarification. The guidance outlines what is expected of both sides in such meetings.
More Talk, Less Work: US FDA Outlines Expectations For Combo Products Discussions
A new FDA draft guidance says manufacturers of combination products should first review existing combination product guidances and submit questions before asking for a combination product agreement meeting with regulators to get clarification. The guidance outlines what is expected of both sides in such meetings.
FDA Approving Complex Generics Pre-ANDA Meeting Requests At Higher Rates
Approval rates for complex-drug pre-ANDA meeting requests are climbing. FDA’s hope is that the meetings will hasten approvals of these hard-to-manufacture generics, which could put a dent in US healthcare costs.